Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission....Revenue Interest Assignment Agreement • August 4th, 2016 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDMENT NO. 1 TO RIAA (this “Amendment”) is made and entered into as of May 9, 2016 by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”), each party to that certain Revenue Interest Assignment Agreement, dated as of July 28, 2015 (as amended, restated, amended and restated, modified and/or supplemented from time to time, the “RIAA”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the RIAA.
Noden Pharma DACInvestment and Stockholders’ Agreement • August 4th, 2016 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
This Investment and Stockholders’ Agreement (this “Agreement”) is entered into as of July 1, 2016, by and among Noden Pharma DAC, a designated activity company limited by shares organized under the Laws of Ireland (the “Company”), PDL BioPharma, Inc., a Delaware corporation (“PDL”), Elie Farah (“Farah”) and the other Persons listed on Annex A (as it may be amended from time to time in accordance with this Agreement) attached hereto (collectively, the “Management Stockholders” and, together with Farah, the “Minority Stockholders”). Each of the parties to this Agreement (other than the Company) and any other Person who shall become a party to or agree to be bound by the terms of this Agreement after the date hereof is sometimes hereinafter referred to as a “Stockholder”.
ContractSupply Agreement • August 4th, 2016 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
